Default company panoramic image
Logo

Optivia Biotechnology Inc.

Optivia is capital-efficient nearly-profitable leader in a fast growing market looking for global and business expansion

  • Stage $3M in TTM Revenue
  • Industry Biotechnology
  • Location Menlo Park, CA, USA
  • Currency USD
  • Employees 16
  • Website optiviabio.com

Company Summary

Optivia delivers capital-efficient innovation in transporter biology and therapeutic development. Its highly differentiated transporter assay services help clients meet regulatory requirement and improve drug response and toxicity. Having become a global leader in transporter assays, Optivia is building an one-stop shop of preclinical research services, by leveraging global assets and capabilities using a novel capital-efficient CRO 2.0 model.

Team

  • Default avatar
    David Lustig
    VP Business Dev.

    Ph.D. in Chemistry, University of Michigan, has worked for Syntex, Roche and CV Therapeutics with roles in drug discovery and business development.

  • Default avatar
    Yong Huang
    President and CEO

    Ph.D. in Bioengineering, UC Berkeley, 14 issued/pending US patents, PI of over $5 million NIH grants, previously co-founded or played instrumental roles at several life science companies.

  • Default avatar
    Dominique Bridon
    EVP and COO

    Ph.D. in Chemistry, Univ. of Paris, over 20 years of scientific excellence and management leadership at top pharmas and public biotech companies. Before joining Optivia, he was Senior VP of Ipsen, heading its drug discovery, translational research and strategic research partnership operations.

  • Default avatar
    Pascal Druzgala
    EVP and CSO

    Ph.D. in Medicinal Chemistry, Univ. of Florida, previously co-founded and served as the CSO of ARYx Therapeutics (NASDAQ:ARYX), has brought many compounds to clinical stage, including presently marketed drugs.

  • Default avatar
    Peter Milner
    EVP Corp. Dev.

    MD and FACC, a board certified physician and cardiologist previously co-founded and served as senior executives at several biotech companies, including CV Therapeutics (Acquired by Gilead) and ARYx Therapeutics (NASDAQ: ARYX), where he helped develop several successful pharmaceuticals.

  • Default avatar
    Alan Mendelson
    General Counsel and Secretary

    Partner at Latham&Watkins, served as the corporate counsel to numerous public and private life science companies.

  • Default avatar
    Charles Hsu
    Board Director

    Partner at Mustang Ventures, a VC firm headquartered in Shanghai, previously a partner at the Walden Group and Advent Intl. and advisor to Bay City Capital and Pappas Ventures, 20 years of investment and startup experience, served as a lead investor and board member for over 25 life science and healthcare companies.

  • Default avatar
    Leslie Benet
    Chairman of SAB

    Professor of Biopharmaceutical Sciences at UC San Francisco. One of the world’s most respected researchers in pharmaceutical sciences, member of the National Academy of Sciences, founding president of American Association of Pharmaceutical Sciences (AAPS), has served as advisor to the FDA and numerous research organizations and drug discovery companies.

Advisors

  • Default avatar
    Alan Mendelson, Latham&Watkins LLP
    Lawyer
    Unconfirmed
    Default avatar
    Andrew Lei CPA
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    Friends and families
    Unconfirmed
    Default avatar
    China Investment Club
    Unconfirmed
    Default avatar
    Latham&Watkins investment fund
    Unconfirmed